Intermittent Episodes of Detectable HIV Viremia in Patients Receiving Nonnucleoside Reverse-Transcriptase Inhibitor-Based or Protease Inhibitor-Based Highly Active Antiretroviral Therapy Regimens Are Equivalent in Incidence and Prognosis | Zendy

Somnuek Sungkanuparph | Zendy; Edgar T. Overton | Zendy; Warren Seyfried | Zendy; Richard K. Groger | Zendy; Victoria J. Fraser | Zendy; William G. Powderly | Zendy

Open Access

Intermittent Episodes of Detectable HIV Viremia in Patients Receiving Nonnucleoside Reverse-Transcriptase Inhibitor-Based or Protease Inhibitor-Based Highly Active Antiretroviral Therapy Regimens Are Equivalent in Incidence and Prognosis

Author(s) -

Somnuek Sungkanuparph,

Edgar T. Overton,

Warren Seyfried,

Richard K. Groger,

Victoria J. Fraser,

William G. Powderly

Publication year - 2005

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/496985

Subject(s) - viremia , medicine , protease inhibitor (pharmacology) , reverse transcriptase inhibitor , reverse transcriptase , incidence (geometry) , virology , antiretroviral therapy , human immunodeficiency virus (hiv) , protease , viral load , pharmacology , enzyme , polymerase chain reaction , biology , physics , optics , biochemistry , gene

Intermittent episodes of detectable human immunodeficiency virus (HIV) viremia (hereafter referred to as "blips") are generally not predictive of subsequent virologic failure. Limited data are available for patients treated with nonnucleoside reverse-transcriptase inhibitor (NNRTI)-based regimens.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research